HUTCHMED (China) Limited (GB:HCM) has released an update.
HUTCHMED (China) Limited is set to present promising results from its Phase III study of sovleplenib for treating primary Immune Thrombocytopenia (ITP) at the EHA2024 Congress, demonstrating a significant durable platelet response compared to placebo. Additional data on sovleplenib’s efficacy in warm antibody autoimmune hemolytic anemia (wAIHA) and results from studies on other investigational therapies for hematological malignancies will also be featured. The company highlights sovleplenib’s rapid response time, tolerable safety profile, and quality of life improvements for patients.
For further insights into GB:HCM stock, check out TipRanks’ Stock Analysis page.
